Northwest & Ethical Investments L.P. Buys 919 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Northwest & Ethical Investments L.P. boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 6.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,319 shares of the medical research company’s stock after buying an additional 919 shares during the quarter. Northwest & Ethical Investments L.P.’s holdings in IQVIA were worth $2,814,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Synergy Asset Management LLC bought a new position in shares of IQVIA in the fourth quarter worth approximately $33,000. Avior Wealth Management LLC raised its stake in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares in the last quarter. Meeder Asset Management Inc. increased its position in IQVIA by 353.7% during the third quarter. Meeder Asset Management Inc. now owns 245 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 191 shares during the last quarter. Versant Capital Management Inc increased its position in IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 93 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in IQVIA during the fourth quarter valued at $60,000. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

IQV has been the topic of a number of research analyst reports. Barclays cut their price target on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Stifel Nicolaus reduced their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, Truist Financial reissued a “buy” rating and set a $263.00 price target (up from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Stock Down 1.5 %

Shares of NYSE:IQV opened at $184.13 on Friday. The stock’s 50-day moving average price is $195.30 and its two-hundred day moving average price is $209.18. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 12-month low of $179.28 and a 12-month high of $256.29. The firm has a market cap of $32.46 billion, a price-to-earnings ratio of 24.55, a PEG ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.